Claims for Patent: 8,741,343

Summary for Patent: 8,741,343

Title:	Method of administering amantadine prior to a sleep period
Abstract:	Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.
Inventor(s):	Went; Gregory T. (Mill Valley, CA), Sathyan; Gayatri (Bangalore, IN), Vermani; Kavita (Fremont, CA), Ganapati; Gangadhara (Palo Alto, CA), Coffee; Michael (Tiburon, CA), Shek; Efraim (Pleasanton, CA), Katdare; Ashok (Berkeley, CA)
Assignee:	Adamas Pharmaceuticals, Inc. (Emeryville, CA)
Application Number:	12/959,321
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,741,343
Patent Claims:	1. A method of administering amantadine, or a pharmaceutically acceptable salt thereof, to a human subject in need thereof, said method comprising the steps of: providing an extended release (ER) composition comprising 220 mg to 445 mg of amantadine, or a pharmaceutically acceptable salt thereof, and at least one release modifying excipient, said composition having a median amantadine Tmax between 8 and 18 hours, as determined by a single dose, fasting human pharmacokinetic study, and orally administering said composition once daily 0 to 4 hours before bedtime to a human subject. 2. The method of claim 1, wherein the method comprises reducing sleep disturbance in a human subject undergoing treatment with amantadine. 3. The method of claim 1, wherein the method comprises treating levodopa-induced dyskinesia in a patient with Parkinson's disease. 4. The method of claim 1, wherein the composition is administered 0 to 3 hours before bedtime. 5. The method of claim 1, wherein the composition is administered 0 to 2 hours before bedtime. 6. The method of claim 1, wherein the composition is administered as two or three unit dosage forms each comprising 110 to 210 mg of extended release amantadine, or a pharmaceutically acceptable salt thereof, and the amantadine, or pharmaceutically acceptable salt thereof in the unit dosage forms together totals 220 mg to 445 mg. 7. The method of claim 1, wherein the composition is administered as two or three unit dosage forms each comprising 130 mg of amantadine, or a pharmaceutically acceptable salt thereof. 8. The method of claim 1, wherein the composition is administered as two or three unit dosage forms each comprising 140 mg of amantadine, or a pharmaceutically acceptable salt thereof. 9. The method of claim 1, wherein the composition is administered as two unit dosage forms each comprising 170 mg of amantadine, or a pharmaceutically acceptable salt thereof. 10. A method of administering amantadine, or a pharmaceutically acceptable salt thereof, to a human subject in need thereof, said method comprising the steps of: providing an extended release (ER) composition comprising 220 mg to 445 mg of amantadine, or a pharmaceutically acceptable salt thereof and at least one release modifying excipient, said composition having a mean Cmax for amantadine of 1.0 to 2.8 ng/mL/mg amantadine and a mean amantadine AUC.sub.0-inf of 40 to 75 nghr/mL/mg, as determined by a single dose, fasting human pharmacokinetic study, and orally administering said composition once daily, 0 to 4 hours before bedtime to a human subject. 11. The method of claim 10, wherein said composition has a mean AUC per mg of amantadine equivalent to a mean AUC per mg of amantadine for a 100 mg tablet of an immediate release formulation of amantadine HCl. 12. The method of claim 10, wherein the method comprises reducing sleep disturbance in a human subject undergoing treatment with amantadine. 13. The method of claim 10, wherein the method comprises treating levodopa-induced dyskinesia in a patient with Parkinson's disease. 14. The method of claim 10, wherein the composition is administered 0 to 3 hours before bedtime. 15. The method of claim 10, wherein the composition is administered 0 to 2 hours before bedtime. 16. The method of claim 10, wherein the composition is administered as one or two or three unit dosage forms each comprising 110 to 210 mg of extended release amantadine, or a pharmaceutically acceptable salt thereof, and the amantadine, or pharmaceutically acceptable salt thereof in the unit dosage forms together totals 220 mg to 445 mg. 17. The method of claim 10, wherein the composition is administered as two or three unit dosage forms each comprising 130 mg of amantadine, or a pharmaceutically acceptable salt thereof. 18. The method of claim 10, wherein the composition is administered as two or three unit dosage forms each comprising 140 mg of amantadine, or a pharmaceutically acceptable salt thereof. 19. The method of claim 10, wherein the composition is administered as two unit dosage forms each comprising 170 mg of amantadine, or a pharmaceutically acceptable salt thereof. 20. The method of claim 10, wherein administration of a dose of the composition to a human subject in a single-dose human pharmacokinetic study provides a mean amantadine Cmax of 1.0 to 2.4 ng/mL/mg. 21. The method of claim 20, wherein said composition has a mean AUC per mg of amantadine equivalent to a mean AUC per mg of amantadine for a 100 mg tablet of an immediate release formulation of amantadine HCl. 22. The method of claim 20, wherein the method comprises reducing sleep disturbance in a human subject undergoing treatment with amantadine. 23. The method of claim 20, wherein the method comprises treating levodopa-induced dyskinesia in a patient with Parkinson's disease. 24. The method of claim 20, wherein the composition is administered 0 to 3 hours before bedtime. 25. The method of claim 20, wherein the composition is administered 0 to 2 hours before bedtime. 26. The method of claim 20, wherein the composition is administered as one or two or three unit dosage forms each comprising 110 to 210 mg of extended release amantadine, or a pharmaceutically acceptable salt thereof, and the amantadine, or pharmaceutically acceptable salt thereof in the unit dosage forms together totals 220 mg to 445 mg. 27. The method of claim 20, wherein the composition is administered as two or three unit dosage forms each comprising 130 mg of amantadine, or a pharmaceutically acceptable salt thereof. 28. The method of claim 20, wherein the composition is administered as two or three unit dosage forms each comprising 140 mg of amantadine, or a pharmaceutically acceptable salt thereof. 29. The method of claim 20, wherein the composition is administered as two unit dosage forms each comprising 170 mg of amantadine, or a pharmaceutically acceptable salt thereof.